Home LiteratureArticle Details
PMID: 19342621 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Myeloid-derived suppressor cells: linking inflammation and cancer.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 182 ·No. 8 ·2009-04-15 ·Pages 4499-506

Ostrand-Rosenberg S, Sinha P

Abstract

Many cancer immunotherapies developed in experimental animals have been tested in clinical trials. Although some have shown modest clinical effects, most have not been effective. Recent studies have identified myeloid-origin cells that are potent suppressors of tumor immunity and therefore a significant impediment to cancer immunotherapy. "Myeloid-derived suppressor cells" (MDSC) accumulate in the blood, lymph nodes, and bone marrow and at tumor sites in most patients and experimental animals with cancer and inhibit both adaptive and innate immunity. MDSC are induced by tumor-secreted and host-secreted factors, many of which are proinflammatory molecules. The induction of MDSC by proinflammatory mediators led to the hypothesis that inflammation promotes the accumulation of MDSC that down-regulate immune surveillance and antitumor immunity, thereby facilitating tumor growth. This article reviews the characterization and suppressive mechanisms used by MDSC to block tumor immunity and describes the mechanisms by which inflammation promotes tumor progression through the induction of MDSC.

MeSH Terms
Animals Cell Differentiation/immunology Humans Inflammation/immunology Myeloid Cells/cytology,immunology,metabolism Neoplasms/immunology S100 Proteins/metabolism T-Lymphocytes/immunology
Chemicals
S100 Proteins
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Ostrand-Rosenberg Suzanne
Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD 21250, USA.
Sinha Pratima
References (99)
99 references, click to expand
  1. Myeloid-derived suppressor cells as regulators of the immune system.
    Nat Rev Immunol. 2009 Mar;9(3):162-74 PMID: 19197294
  2. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis.
    Carcinogenesis. 2008 Oct;29(10):2035-43 PMID: 18689872
  3. Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells.
    Blood. 2008 Nov 15;112(10):4080-9 PMID: 18753637
  4. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice.
    Blood. 2008 Jun 15;111(12):5457-66 PMID: 18375791
  5. Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2.
    Cancer Res. 2008 May 1;68(9):3467-75 PMID: 18451175
  6. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.
    Cancer Res. 2006 Jan 15;66(2):1123-31 PMID: 16424049
  7. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis.
    J Exp Med. 2007 Jun 11;204(6):1463-74 PMID: 17548519
  8. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.
    Cancer Res. 2007 May 1;67(9):4507-13 PMID: 17483367
  9. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.
    Cancer Res. 2007 Oct 15;67(20):10019-26 PMID: 17942936
  10. VEGF-targeted therapy: mechanisms of anti-tumour activity.
    Nat Rev Cancer. 2008 Aug;8(8):579-91 PMID: 18596824
  11. Altered macrophage differentiation and immune dysfunction in tumor development.
    J Clin Invest. 2007 May;117(5):1155-66 PMID: 17476345
  12. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells.
    Cancer Immunol Immunother. 2008 Oct;57(10):1493-504 PMID: 18322683
  13. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules.
    J Leukoc Biol. 2007 Jan;81(1):28-37 PMID: 16943388
  14. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response.
    Nat Rev Immunol. 2004 Sep;4(9):675-87 PMID: 15343367
  15. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance.
    J Exp Med. 2005 Dec 19;202(12):1627-33 PMID: 16365146
  16. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells.
    J Immunol. 2008 Oct 1;181(7):4666-75 PMID: 18802069
  17. Regulation of immune responses by L-arginine metabolism.
    Nat Rev Immunol. 2005 Aug;5(8):641-54 PMID: 16056256
  18. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice.
    Cancer Cell. 2008 Nov 4;14(5):408-19 PMID: 18977329
  19. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.
    Nat Med. 2007 Jul;13(7):828-35 PMID: 17603493
  20. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression.
    J Immunol. 2006 Jan 1;176(1):284-90 PMID: 16365420
  21. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells.
    J Immunol. 2005 Oct 1;175(7):4583-92 PMID: 16177103
  22. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress.
    J Immunol. 2006 Feb 15;176(4):2085-94 PMID: 16455964
  23. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.
    Blood. 2008 Apr 15;111(8):4233-44 PMID: 18272812
  24. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.
    Cancer Cell. 2008 Jan;13(1):23-35 PMID: 18167337
  25. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.
    J Immunol. 2002 Jan 15;168(2):689-95 PMID: 11777962
  26. Cancer immunology. Cancer's bulwark against immune attack: MDS cells.
    Science. 2008 Jan 11;319(5860):154-6 PMID: 18187637
  27. Cyclooxygenase-2 inhibitors in tumorigenesis (part I).
    J Natl Cancer Inst. 1998 Oct 21;90(20):1529-36 PMID: 9790545
  28. Subsets of myeloid-derived suppressor cells in tumor-bearing mice.
    J Immunol. 2008 Oct 15;181(8):5791-802 PMID: 18832739
  29. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein.
    J Exp Med. 2008 Sep 29;205(10):2235-49 PMID: 18809714
  30. Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations.
    J Autoimmun. 2008 Dec;31(4):354-61 PMID: 18838247
  31. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics.
    J Leukoc Biol. 2008 May;83(5):1136-44 PMID: 18285406
  32. Chronic inflammation and cancer.
    Oncology (Williston Park). 2002 Feb;16(2):217-26, 229; discussion 230-2 PMID: 11866137
  33. L-arginine metabolism in myeloid cells controls T-lymphocyte functions.
    Trends Immunol. 2003 Jun;24(6):302-6 PMID: 12810105
  34. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
    Clin Cancer Res. 2005 Sep 15;11(18):6713-21 PMID: 16166452
  35. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.
    Cancer Res. 2005 Dec 15;65(24):11743-51 PMID: 16357187
  36. The role of complement in inflammatory diseases from behind the scenes into the spotlight.
    Am J Pathol. 2007 Sep;171(3):715-27 PMID: 17640961
  37. Modulation of the antitumor immune response by complement.
    Nat Immunol. 2008 Nov;9(11):1225-35 PMID: 18820683
  38. Nonsteroidal anti-inflammatory drugs and cancer prevention.
    Annu Rev Med. 2000;51:511-23 PMID: 10774479
  39. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway.
    Cancer Res. 2005 Oct 15;65(20):9525-35 PMID: 16230418
  40. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host.
    Blood. 2007 May 15;109(10):4336-42 PMID: 17244679
  41. CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer.
    Ann Otol Rhinol Laryngol. 2000 Aug;109(8 Pt 1):749-54 PMID: 10961808
  42. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs.
    Epidemiology. 2001 Jan;12(1):88-93 PMID: 11138826
  43. Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice.
    Mech Ageing Dev. 2007 Nov-Dec;128(11-12):672-80 PMID: 18036633
  44. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance.
    Immunol Rev. 2008 Apr;222:155-61 PMID: 18364000
  45. Mechanisms and functional significance of tumour-induced dendritic-cell defects.
    Nat Rev Immunol. 2004 Dec;4(12):941-52 PMID: 15573129
  46. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells.
    J Immunol. 2005 Dec 15;175(12):8200-8 PMID: 16339559
  47. Immature myeloid cells and cancer-associated immune suppression.
    Cancer Immunol Immunother. 2002 Aug;51(6):293-8 PMID: 12111117
  48. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.
    Cancer Immunol Immunother. 2009 Jan;58(1):49-59 PMID: 18446337
  49. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.
    J Immunol. 2003 Jan 1;170(1):270-8 PMID: 12496409
  50. Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation: exploring obscure relationships.
    Annu Rev Immunol. 1984;2:219-37 PMID: 6152690
  51. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
    J Clin Oncol. 2007 Jun 20;25(18):2546-53 PMID: 17577033
  52. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.
    Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):721s-726s PMID: 17255300
  53. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells.
    J Immunol. 2001 May 1;166(9):5398-406 PMID: 11313376
  54. Role of C5a in inflammatory responses.
    Annu Rev Immunol. 2005;23:821-52 PMID: 15771587
  55. TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs.
    J Immunol. 2006 Oct 1;177(7):4763-72 PMID: 16982917
  56. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.
    Nat Med. 2005 Dec;11(12):1314-21 PMID: 16288283
  57. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.
    J Immunol. 2005 Jan 15;174(2):636-45 PMID: 15634881
  58. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans.
    J Clin Invest. 2008 Dec;118(12):4036-48 PMID: 19033672
  59. Cancer-related inflammation.
    Nature. 2008 Jul 24;454(7203):436-44 PMID: 18650914
  60. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species.
    J Leukoc Biol. 2003 Aug;74(2):186-96 PMID: 12885935
  61. CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis.
    J Immunol. 2007 Oct 15;179(8):5228-37 PMID: 17911608
  62. Inflammation and cancer: back to Virchow?
    Lancet. 2001 Feb 17;357(9255):539-45 PMID: 11229684
  63. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.
    Cancer Res. 2006 Sep 15;66(18):9299-307 PMID: 16982775
  64. Increased levels of immune inhibitory CD34+ progenitor cells in the peripheral blood of patients with node positive head and neck squamous cell carcinomas and the ability of these CD34+ cells to differentiate into immune stimulatory dendritic cells.
    Otolaryngol Head Neck Surg. 2001 Sep;125(3):205-12 PMID: 11555755
  65. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.
    J Immunol. 1998 Nov 15;161(10):5313-20 PMID: 9820504
  66. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection.
    J Immunol. 2005 May 15;174(10):6095-104 PMID: 15879104
  67. Inflammation and cancer.
    Nature. 2002 Dec 19-26;420(6917):860-7 PMID: 12490959
  68. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells.
    Cancer Res. 2003 Jun 15;63(12):3058-60 PMID: 12810627
  69. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.
    Cancer Res. 2005 Apr 15;65(8):3044-8 PMID: 15833831
  70. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
    J Exp Med. 2003 Dec 1;198(11):1741-52 PMID: 14657224
  71. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor.
    Clin Cancer Res. 1995 Jan;1(1):95-103 PMID: 9815891
  72. Myeloid suppressor cell-associated immune dysfunction in CSA1M fibrosarcoma tumor-bearing mice.
    Cancer Sci. 2007 Jun;98(6):882-9 PMID: 17433038
  73. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function.
    Blood. 2008 Jan 1;111(1):219-28 PMID: 17885078
  74. IL-1 is required for tumor invasiveness and angiogenesis.
    Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2645-50 PMID: 12598651
  75. S100A8 and S100A9 in inflammation and cancer.
    Biochem Pharmacol. 2006 Nov 30;72(11):1622-31 PMID: 16846592
  76. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.
    Cancer Res. 2004 Sep 1;64(17):6337-43 PMID: 15342423
  77. Tumor growth increases Ia- macrophage synthesis of tumor necrosis factor-alpha and prostaglandin E2: changes in macrophage suppressor activity.
    J Leukoc Biol. 1993 May;53(5):550-8 PMID: 8388910
  78. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.
    J Clin Invest. 2006 Oct;116(10):2777-90 PMID: 17016559
  79. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma.
    J Exp Med. 2005 Oct 3;202(7):931-9 PMID: 16186186
  80. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.
    J Immunol. 2004 Jan 15;172(2):989-99 PMID: 14707072
  81. Pro-inflammatory prostaglandins and progression of colorectal cancer.
    Cancer Lett. 2008 Aug 28;267(2):197-203 PMID: 18406516
  82. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.
    J Immunol. 2001 Jan 1;166(1):678-89 PMID: 11123353
  83. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.
    Blood. 2000 Dec 1;96(12):3838-46 PMID: 11090068
  84. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.
    J Immunol. 2007 Jul 15;179(2):977-83 PMID: 17617589
  85. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.
    Gastroenterology. 2008 Sep;135(3):871-81, 881.e1-5 PMID: 18674538
  86. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4.
    J Leukoc Biol. 2009 Jun;85(6):996-1004 PMID: 19261929
  87. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.
    Cancer Res. 2008 Jul 1;68(13):5439-49 PMID: 18593947
  88. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis.
    Nat Cell Biol. 2006 Dec;8(12):1369-75 PMID: 17128264
  89. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.
    Cancer Res. 2006 Jul 1;66(13):6807-15 PMID: 16818658
  90. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.
    Cancer Res. 2003 Aug 1;63(15):4441-9 PMID: 12907617
  91. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro.
    Eur J Immunol. 2005 Dec;35(12):3533-44 PMID: 16331707
  92. Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: gamma interferon plus tumor necrosis factor alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis.
    Cancer Res. 1992 Nov 15;52(22):6335-40 PMID: 1423279
  93. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II).
    J Natl Cancer Inst. 1998 Nov 4;90(21):1609-20 PMID: 9811310
  94. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation.
    Clin Chim Acta. 2004 Jun;344(1-2):37-51 PMID: 15149869
  95. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.
    Immunol Rev. 2008 Apr;222:162-79 PMID: 18364001
  96. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
    Gastroenterology. 2008 Jul;135(1):234-43 PMID: 18485901
  97. Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice.
    Blood. 2000 Jan 1;95(1):212-20 PMID: 10607705
  98. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.
    J Immunol. 2009 Jan 1;182(1):240-9 PMID: 19109155
  99. Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor.
    Clin Exp Metastasis. 1999;17(10):881-8 PMID: 11089887
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
1550-6606
DOI
10.4049/jimmunol.0802740
Published
2009-04-15
Pages
4499-506
Language
English
Region
United States
NLM ID
2985117R
PMCID
PMC2810498
Subset
IM
Grants
NCI NIH HHS · R01 CA115880-04 · United States
NCI NIH HHS · R01 CA084232-07 · United States
NCI NIH HHS · R01 CA115880 · United States
NCI NIH HHS · R01CA115880 · United States
NCI NIH HHS · R01 CA084232 · United States
NCI NIH HHS · R01CA84232 · United States
External Links
PubMed source DOI: 10.4049/jimmunol.0802740 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2